5,250 Shares in RxSight, Inc. (NASDAQ:RXST) Acquired by Thompson Davis & CO. Inc.

Thompson Davis & CO. Inc. bought a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,250 shares of the company’s stock, valued at approximately $212,000.

Other large investors have also added to or reduced their stakes in the company. RiverPark Advisors LLC grew its stake in RxSight by 70.0% in the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after acquiring an additional 275 shares during the period. HighTower Advisors LLC grew its stake in RxSight by 7.3% in the third quarter. HighTower Advisors LLC now owns 13,256 shares of the company’s stock valued at $369,000 after acquiring an additional 899 shares during the period. BluePath Capital Management LLC acquired a new stake in RxSight in the third quarter valued at approximately $32,000. Bank of New York Mellon Corp grew its stake in RxSight by 3.0% in the third quarter. Bank of New York Mellon Corp now owns 106,203 shares of the company’s stock valued at $2,962,000 after acquiring an additional 3,132 shares during the period. Finally, SG Americas Securities LLC grew its stake in RxSight by 95.6% in the third quarter. SG Americas Securities LLC now owns 9,970 shares of the company’s stock valued at $278,000 after acquiring an additional 4,873 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Buying and Selling at RxSight

In other RxSight news, Director William J. Phd Link sold 28,250 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $49.67, for a total value of $1,403,177.50. Following the sale, the director now directly owns 24,248 shares in the company, valued at $1,204,398.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Bakker Juliet Tammenoms acquired 4,000 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were bought at an average cost of $50.38 per share, for a total transaction of $201,520.00. Following the purchase, the director now owns 25,840 shares in the company, valued at approximately $1,301,819.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William J. Phd Link sold 28,250 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $49.67, for a total value of $1,403,177.50. Following the sale, the director now owns 24,248 shares in the company, valued at $1,204,398.16. The disclosure for this sale can be found here. Insiders have sold a total of 94,869 shares of company stock worth $4,771,244 over the last ninety days. 21.13% of the stock is currently owned by company insiders.

RxSight Price Performance

Shares of RXST traded down $1.13 during mid-day trading on Tuesday, hitting $52.13. The stock had a trading volume of 305,555 shares, compared to its average volume of 424,615. The firm has a market cap of $1.94 billion, a P/E ratio of -36.45 and a beta of 1.22. The business has a fifty day moving average price of $52.48 and a 200-day moving average price of $42.34. RxSight, Inc. has a 52 week low of $17.59 and a 52 week high of $58.21.

RxSight (NASDAQ:RXST) last issued its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.10. The firm had revenue of $28.58 million for the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. As a group, research analysts expect that RxSight, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RXST has been the subject of a number of research reports. Stifel Nicolaus raised their price objective on RxSight from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of RxSight in a research report on Thursday, April 11th. Oppenheimer lifted their target price on RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, JPMorgan Chase & Co. lifted their target price on RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight has a consensus rating of “Buy” and an average price target of $49.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.